Insider Purchases: Inside the Buy

Tag: Biotech Stocks

Bezuclastinib vial on biotech lab bench, with clinical trial data and stock chart rising in background—symbolizing COGT’s potential breakthrough

Cogent Biosciences (COGT): The Biotech with a Plan, a Billion Cells, and a Bezuclastinib

Insiders are buying, trials are working, and Cogent just raised $230M. Meet bezuclastinib—the biotech drug with a Marvel name and real potential. 🧬💥

Read entire article

Tags: Bezuclastinib, Biotech Stocks, Clinical Trials, COGT, Cole Pinnow, Fairmount Funds, Funanc1al Insider Series, Funanc1alBiotech, Funanc1alEdge, Funanc1alFinance, Funanc1alFun, Funanc1alHealth, Funanc1alHumor, Funanc1alInsiders, Funanc1alInsiderSeries, Funanc1alInvesting, Funanc1alPharma, Funanc1alStocks, GIST, Insider Buying, Speculative Plays, Systemic Mastocytosis
A vibrant infographic showing a DNA double helix, syringes, a downward-sloping stock chart turning upward, and a confident CEO dropping a golden coin into the Moderna logo, labeled “$5M Insider Buy”

Moderna: Messenger RNA Medicines Powerhouse Sends A New Message — “Discount!”

Insiders dropped $6M on Moderna stock. With a massive mRNA pipeline and deep-pocketed backers, is this biotech beast ready to roar again?

Read entire article

Tags: Baillie Gifford, Biotech Stocks, Cash Burn, CEO insider buying, Checkpoint Immunotherapy, COVID, Cytomegalovirus, Director Insider Buying, Finance with Fun, Funanc1al Insider Series, Funanc1alInsiderSeries, Healthcare Innovation, insider buying, Insider Buys, Insider Purchases, InsiderActivity, InsiderBuying, InsiderPurchases, InsiderScoops, Investment Ideas, Moderna, MRNA, MRNA Stock, Norovirus, Oncology, Pharma, R&D, Rare diseases, RSV, Stock Market, Vaccine Stocks, Valuation Biotech, Wall Street
Cartoon-style DNA strand with a rollercoaster winding through it. Investors scream in biotech lab coats as the track dips next to a “+62% Revenue” sign and then plunges toward “–43% Stock” territory.

🧬 GeneDx (WGS): Profit, Progress, and a 43% Plunge? Sounds Genetic.

GeneDx is profitable. Revenues are growing. Innovation is real. So why did the stock tank 43%? Here’s your deep-dive into the DNA of a biotech rollercoaster—with humor, icons, and a whole lot of exome.

Read entire article

Tags: Biotech Stocks, Emerging Growth, Exome Sequencing, Fabric Genomics, Funanc1al, Funanc1al for Investors, Funanc1al Health, Funanc1al Investing, Funanc1alInvesting, Funny Finance, GeneDx, Genetic Diagnostics, Genomics, Healthcare Innovation, Medical Breakthroughs, Pediatric Genomics, Short Squeeze Watch, Stamford Tech, Stock Market Humor, Wall Street Volatility, WGS, WGS Stock
A colorful digital illustration featuring Moderna's logo (MRNA) with a rising stock chart, symbolizing the biotech company's potential growth and innovation in gene-based therapies.

Moderna (MRNA): The Biotech Rollercoaster – Will This Gene Editor Reach the Top? 🎢💉

Moderna (MRNA) might be on the downhill since its peak in 2021, but its remarkable mRNA platform is fueling new therapeutic breakthroughs. With strong insider bets, a healthy pipeline, and institutional backing, Moderna could be an intriguing long-term play for investors. However, risks like intense competition and COVID sales deceleration remain. Should you bet on Moderna’s future or stay on the sidelines? Here’s what you need to know.

Read entire article

Tags: Biotech Investments, Biotech Stocks, Biotechnology, Biotechnology Innovation, COVID Vaccine, Gene Editing, healthcare stocks, Insider Purchases, Investment Insights, Moderna, Moderna CEO, mRNA, Paul Sagan, pharmaceutical stocks, Stephane Bancel